Author

S. T. Killarney

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. M. Pendergast· 1 shared A. Puissant· 1 shared A. R. Martin· 1 shared B. Mayro· 1 shared C. Cerda-Smith· 1 shared C. F. Bassil· 1 shared C. Favreau· 1 shared D. M. Lonard· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. M. Pendergast

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

MCB-613 exploits a collateral sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer through covalent inhibition of KEAP1

C. F. Bassil, G. R. Anderson, B. Mayro, K. N. Askin, P. S. Winter, S. Gruber, T. M. Hall, J. P. Hoj, C. Cerda-Smith, H. M. Hutchinson, S. T. Killarney, K. R. Singleton, L. Qin, K. Jubien-Girard, C. Favreau, , K. C. Wood

The paper identifies MCB-613 as a compound that targets KEAP1 in EGFR inhibitor-resistant NSCLC cells, exploiting its selective essentiality through covalent inhibition.

bioRxiv · Jan 17, 2023 · PreprintCancer Biology